PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer

Targeting immune checkpoint molecules such as programmed death ligand-1 (PDL1) is an emerging strategy for anti-cancer therapy. However, transient expression of PDL1 and difficulty in tumor stroma penetration has limited the utility of anti-PDL1 therapy. To overcome these limitations, we report a ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Sau, Samaresh, Petrovici, Alex, Alsaab, Hashem O., Bhise, Ketki, Iyer, Arun K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406713/
https://www.ncbi.nlm.nih.gov/pubmed/30781490
http://dx.doi.org/10.3390/cancers11020232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406713/
https://www.ncbi.nlm.nih.gov/pubmed/30781490
http://dx.doi.org/10.3390/cancers11020232

Ejemplares similares